Investor Relations

HOME>Investor Relations

February 20		Mitsubishi Tanabe Pharma Received Notice of Request for Arbitration
February 14		FDA accepted an Investigational New Drug Application for MT-8633, an ADC Targeting cMet Positive Solid Tumors
February 12		First Initiative in Digital Medicine Notice Regarding the Start of a Demonstration Project for TOMOCO, a Diabetes Care App
February 7		IR Meeting for FY2018 3rd Quarter Business Results[Transcript]
February 6		Swissmedic approves RADICAVA, Japan-originated ALS treatment
February 4		IR Meeting for FY2018 3rd Quarter Business Results[Material][Audio]
February 4		Announcement of FY2018 3rd Quarter Financial Results ⇒R&D Pipeline "State of New Product Development"
February 4		Notice Regarding Conclusion of Stock Transfer Agreement for Tanabe Seiyaku Yoshiki Factory Co., Ltd.